Study of Heart Transplant Outcomes in HIV-Positive Adults Receiving Hearts from HIV-Positive or HIV-Negative Donors

What this Trial Is About

Researchers are investigating the safety and outcomes of heart transplants in people living with HIV who receive hearts from either HIV-positive or HIV-negative deceased donors. This study aims to understand whether receiving a heart from an HIV-positive donor is as safe and effective as receiving one from an HIV-negative donor. The trial also explores long-term health effects and mortality in HIV-positive heart transplant recipients, expanding knowledge in thoracic organ transplantation under the HIV Organ Policy Equity Act HOPE Act. Participants who meet transplant eligibility will be offered hearts from either HIV-positive or HIV-negative donors based on availability, creating two main study groups. Those who accept an HIV-positive donor heart form the HIV DR group, while those receiving HIV-negative donor hearts form the HIV D-R group. The study intervention is the receipt of the heart transplant no additional experimental treatments or blood samples will be collected beyond standard care. After transplantation, participants will be followed through regular clinical visits at 1, 2, and 3 years post-transplant, with data collected from medical records. Researchers will assess outcomes like survival, graft function, rejection episodes, and serious adverse events up to four years after transplant. Overall participation involves routine evaluations without extra procedures, focusing on chart reviews to monitor transplant success and participant health over time.

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients